Navigation Links
Decision Diagnostic Corp. (Formerly InstaCare) Announces 10% Stock Dividend
Date:12/6/2011

LOS ANGELES, Dec. 6, 2011 /PRNewswire/ -- Decision Diagnostics Corp., formerly known as InstaCare Corp. (OTCQB: ISCRD), a leading provider of prescription diagnostics, home testing products for the chronically ill, a leading fulfillment provider of direct to patient diabetes programs, and a leading developer of revolutionary cell phone centric e-health products and technologies, today announced that the Board of Directors has approved the payment of a 10 percent stock dividend to all shareholders of record as of December 20, 2011. The dividend will be payable to shareholders of record no later than December 31, 2011.

Decision Diagnostics also announced that management is in the process of evaluating potential acquisitions to bolster the company's competitive position. The Board is committed to streamlining and simplifying the company's capital structure for the benefit of shareholders and to help improve the company's M&A capabilities. Accordingly, the Board has decided to reduce the authorized share count from 1.75 billion to approximately 495 million (494,995,000).  

Mr. Berman, CFO and Secretary commented, "We are moving earnestly to complete the strategic initiatives necessary to position Decision Diagnostics Corp. for a national listing on a major exchange. This proposed national listing, and our improved capital structure, are appropriate for a company of our size with the growth dynamics we have before us. Our position as a full-service provider of a wide and growing range of at-home diagnostics, poised to become a major player in the $20 billion worldwide market for at-home testing of blood glucose. A national listing will significantly enhance the visibility of our stock and improve liquidity, both to the long-term benefit of our loyal shareholders. In addition, the Board of Directors wanted to reward our shareholders with a one-time 10% stock dividend, and we are excited to announce that today."

Mr. Berman concluded, "We are in advanced discussions with potential targets and hope to have M&A-related announcements in the coming days.  We are redoubling our efforts to close these potential M&A activities before the end of the year. Our actions follow the previously announced 1 for 14 reverse split, effective December 1, 2011. These changes the company's capital structure are part of an effort to qualify to have our common stock to be listed on a national exchange, with the goal of applying to the NASDAQ Bx exchange early in 2012."

For more information about Decision Diagnostics Corp., Pharma Tech Solutions, Inc. and/or its revolutionary MD@Hand cell phone centric technologies, please visit the Decision Diagnostics Corp. web site www.decisiondiagnostics.com or www.pharmatechdirect.com, or call the company at (805) 446-2973.

Forward-Looking Statements

This news release contains forward-looking statements about our business, or financial condition and prospects that reflect our assumptions and beliefs based on information currently available. We can give no assurance that the expectations indicated by such forward-looking statements will be realized. There may be other risks and circumstances that we are unable to predict. When used in this news release, words such as "believes," "expects," "intends," "plans," "anticipates," "estimates" and similar expressions are intended to identify forward-looking statements, although there may be certain forward-looking statements not accompanied by such expressions.


'/>"/>
SOURCE Decision Diagnostics Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Commissioner announces Avastin decision
2. Sanofi Pasteur Launches Nationwide Education Campaign to Help Parents Make Informed Decisions about Immunization
3. Pharmaceutical Executives Use New Search Function for Data-Informed Decision-Making
4. e-Zassi and UBM Canon Partner to Provide Online Medical Device Decision Support Tools at Qmed.com
5. American College of Medical Genetics Applauds HHS Secretarys Decision to Expand Newborn Screening to Include Critical Congenital Heart Disease
6. Experis Recognizes National Healthcare IT Week, Provides Tips for ICD-10 Assessment Decision
7. QIAGEN Completes Second U.S.Submission for Companion Diagnostic to Guide Treatment Decisions in Colorectal Cancer
8. DecisionView StudyOptimizer 4.3™ Enhances Market-Leading Enrollment Optimization Solution With Greater Visibility Into Site Performance and Cost Forecasting
9. Watson Confirms Favorable Appeals Court Decision in Mucinex(R) Patent Suit
10. ECRI Institute Launches Market Analytics Tool to Help Hospitals Make More Informed Capital Purchasing Decisions
11. ImpactRx Measures How Patient Brand Requests Drive Physician Treatment Decisions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Any dentist who has made an implant supported ... Many of them do not even offer this as a ... laboratory costs involved. And those who ARE able to offer ... high cost that the majority of today,s patients would not ... Zadeh , founder of Dental Evolutions Inc. and inventor of ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Issue 52" report to their offering. ... treatment creates a favourable commercial environment for MedImmune to enter. ... base that will serve to drive considerable growth for effective ... serve to cap sales considerably, but development is still in ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... ... of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum Wage’ ... 2020 and then adjusting it yearly to increase at the same rate as the median ... floor does not erode again, and make future increases more predictable. , The company is ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, ... journal articles published in Emergency Medicine Practice and Pediatric Emergency Medicine ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative Solutions ... initiated cultivation and processing operations at its production facility, and opened its first ... is the manufacturer of a complete system of proactive air and surface purification ...
(Date:6/24/2016)... ... , ... National recruitment firm Slone Partners is pleased to announce ... experience, as Vice President of North American Capital Sales at HTG Molecular . ... sales team in the commercialization of the HTG EdgeSeq system and associated reagents in ...
(Date:6/24/2016)... ... June 24, 2016 , ... Today, MTI-GlobalStem, a provider ... and other difficult to transfect cells, announces its launch of the PluriQ™ G9™ ... Editing System is a complete system for culturing and transfecting human pluripotent ...
Breaking Medicine News(10 mins):